Insmed Incorporated (NASDAQ:INSM) CEO Sells $1,458,562.50 in Stock

Insmed Incorporated (NASDAQ:INSM) CEO William Lewis sold 18,750 shares of the stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $77.79, for a total transaction of $1,458,562.50. Following the sale, the chief executive officer now owns 334,186 shares of the company’s stock, valued at approximately $25,996,328.94. This represents a 5.31 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

William Lewis also recently made the following trade(s):

• On Tuesday, February 18th, William Lewis sold 18,750 shares of Insmed stock. The stock was sold at an average price of $81.03, for a total transaction of $1,519,312.50.
• On Thursday, February 6th, William Lewis sold 79,350 shares of Insmed stock. The stock was sold at an average price of $80.90, for a total transaction of $6,419,415.00.
• On Monday, February 3rd, William Lewis sold 18,750 shares of Insmed stock. The stock was sold at an average price of $77.94, for a total transaction of $1,461,375.00.
• On Wednesday, January 15th, William Lewis sold 31,805 shares of Insmed stock. The stock was sold at an average price of $70.18, for a total transaction of $2,232,074.90.
• On Friday, January 10th, William Lewis sold 2,978 shares of Insmed stock. The stock was sold at an average price of $63.36, for a total transaction of $188,686.08.
• On Tuesday, January 7th, William Lewis sold 8,218 shares of Insmed stock. The stock was sold at an average price of $66.02, for a total transaction of $542,552.36.
• On Thursday, January 2nd, William Lewis sold 18,750 shares of Insmed stock. The stock was sold at an average price of $69.84, for a total transaction of $1,309,500.00.
• On Thursday, December 19th, William Lewis sold 18,750 shares of Insmed stock. The stock was sold at an average price of $69.91, for a total transaction of $1,310,812.50.

Insmed Price Performance

Shares of INSM opened at $74.89 on Friday. Insmed Incorporated has a twelve month low of $21.92 and a twelve month high of $84.91. The company has a quick ratio of 5.99, a current ratio of 6.37 and a debt-to-equity ratio of 2.03. The firm has a 50 day moving average of $75.66 and a 200 day moving average of $73.83. The company has a market capitalization of $13.56 billion, a P/E ratio of -13.40 and a beta of 1.28.

Insmed (NASDAQ:INSM) last issued its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.17) by ($0.15). Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. The company had revenue of $104.44 million during the quarter, compared to analysts’ expectations of $102.31 million. As a group, equities research analysts anticipate that Insmed Incorporated will post -4.56 earnings per share for the current fiscal year.

Analysts Set New Price Targets

INSM has been the subject of a number of research reports. Cantor Fitzgerald reissued an “overweight” rating on shares of Insmed in a research note on Wednesday, February 19th. Truist Financial raised their target price on shares of Insmed from $105.00 to $108.00 and gave the company a “buy” rating in a research note on Friday, February 21st. Morgan Stanley raised their target price on shares of Insmed from $85.00 to $90.00 and gave the company an “overweight” rating in a research note on Thursday, February 6th. Royal Bank of Canada started coverage on shares of Insmed in a research note on Tuesday, February 25th. They set an “outperform” rating and a $100.00 target price for the company. Finally, Wells Fargo & Company raised their target price on shares of Insmed from $85.00 to $107.00 and gave the company an “overweight” rating in a research note on Wednesday, February 19th. One investment analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Insmed currently has an average rating of “Moderate Buy” and a consensus target price of $93.33.

Institutional Investors Weigh In On Insmed

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its holdings in Insmed by 6.3% in the fourth quarter. Vanguard Group Inc. now owns 18,218,973 shares of the biopharmaceutical company’s stock worth $1,257,838,000 after purchasing an additional 1,075,796 shares during the last quarter. Darwin Global Management Ltd. boosted its stake in shares of Insmed by 23.5% during the 4th quarter. Darwin Global Management Ltd. now owns 12,960,538 shares of the biopharmaceutical company’s stock worth $894,796,000 after acquiring an additional 2,463,261 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its stake in shares of Insmed by 1.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 12,704,410 shares of the biopharmaceutical company’s stock worth $877,113,000 after acquiring an additional 123,429 shares during the last quarter. Capital International Investors boosted its stake in shares of Insmed by 9.1% during the 4th quarter. Capital International Investors now owns 7,116,997 shares of the biopharmaceutical company’s stock worth $491,357,000 after acquiring an additional 593,206 shares during the last quarter. Finally, Geode Capital Management LLC boosted its stake in shares of Insmed by 7.2% during the 4th quarter. Geode Capital Management LLC now owns 4,087,143 shares of the biopharmaceutical company’s stock worth $282,243,000 after acquiring an additional 273,759 shares during the last quarter.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.